Introduction {#Sec1}
============

Chemotherapy-induced gastrointestinal mucositis (CIGM) can not only necessitate treatment delay or cessation but also, more importantly, represent a significant burden to healthcare costs and patient quality of life \[[@CR1]\]. Symptoms include diarrhoea, abdominal pain and weight loss and are a direct result of damage to the epithelial layer of the gut, which increases permeability, induces inflammation and ulceration, and prevents adequate nutrient uptake. Alterations to the gut microbiome are also associated with mucositis, which can further drive the inflammatory state \[[@CR2], [@CR3]\]. At present, treatment for mucositis is supportive only; new interventions intended to prevent and/or reduce mucositis are being investigated and include growth factors, anti-inflammatories, nutritional supplements and medicinal foods \[[@CR4]\].

Oral administration of serum-derived immunoglobulin, derived from human or animal serum or plasma, has been shown to improve symptoms of disease states with an inflammatory basis, such as viral gastroenteritis in children \[[@CR5]\], malnourishment in children \[[@CR6]\], weaning in pigs \[[@CR7]\], irritable bowel syndrome with diarrhoea (IBS-D) \[[@CR8], [@CR9]\] and HIV-induced enteropathy \[[@CR10]\]. Serum-derived bovine immunoglobulin/protein isolate (SBI) is obtained through the spray-drying of bovine plasma and is available commercially as EnteraGam™ (Entera Health Inc., Cary, NC, USA), which is regulated by the FDA as a medical food in the management of IBS-D \[[@CR8], [@CR9]\] and HIV-associated enteropathy \[[@CR10]\].

The aforementioned enteropathic conditions are associated with abdominal pain, weight loss, malabsorption and diarrhoea, and as such have a similar symptom profile to CIGM. With this in mind, the rationale for the current study was to determine whether SBI had similar positive effects on irinotecan-induced GI mucositis in a Dark Agouti rat model.

Methods and materials {#Sec2}
=====================

Animals {#Sec3}
-------

Animal work complied with the National Health and Medical Research Council (Australia) Code for the Care and Use of Animals for Scientific Purposes (8th edition, 2013). Ethics approval was obtained from both University of Adelaide and SA Pathology. Animals were group-housed (four animals/cage) in standard conditions of light and dark cycles and had food and water available ad libitum.

Female Dark Agouti rats (*n* = 192) of 150--180 g were randomly assigned to treatment groups. Our models of chemotherapy-induced mucositis focus on growing (non-adult) animals, as younger animals are more responsive to chemotherapy.

Serum-derived bovine immunoglobulin/protein isolate {#Sec4}
---------------------------------------------------

SBI was provided by Entera Health Inc. as a \>90 % (*w*/*w*) protein powder, comprised of \>50 % immunoglobulin G (IgG), and a mixture of other serum proteins similar to that found in milk and colostrum. Additional ingredients are dextrose and trace amounts of sunflower lecithin. SBI is free of milk products (lactose, casein, whey), gluten, dye and soy, and is manufactured in accordance with current Good Manufacturing Practice (cGMP) for medical foods \[[@CR9]\]. Powdered SBI was mixed with water for dosing as recommended in the prescribing information, and the doses used in this study (250 and 500 mg/kg) were based around the daily human equivalent dose (\~5--10 g/day \[[@CR10], [@CR8], [@CR9]\]); average gavage volume was 1.5--2 mL.

Experimental plan {#Sec5}
-----------------

On experimental day 4, animals were orally gavaged twice daily (at 8 a.m. and 3 p.m.) with either 250 or 500 mg/kg of SBI, or an equivalent volume of 0.09 % saline. This was continued for 11 days. On day 0, 200 mg/kg of irinotecan was administered intraperitoneally to appropriate groups, with 0.01 mg/kg of subcutaneous atropine to prevent a cholinergic reaction.

Animals were monitored for 6 h following irinotecan administration for clinical signs of stress; at this time point, eight animals in each treatment group were killed. Approximately 4 mL of blood was collected for analysis. Animals were dissected; intestinal tissue was removed and flushed with chilled saline, and organs were removed, then all tissues were weighed and fixed in formalin. Remaining animals continued to receive twice daily oral gavage; on days 2, 4 and 6 post-treatment, eight animals in each group were killed. Animals were weighed and monitored for clinical symptoms of stress and diarrhoea up to four times daily; these include piloerection, stress marks (porphyrin discharge from Harderian glands), changes in movement, temperament and posture, reduction in temperature, weight loss, and reduced food and water intake. These symptoms were scored as 0 (none), 1 (mild), 2 (moderate) or 3 (severe), and incidence data were charted. Incidence of irinotecan-induced diarrhoea was also charted for each animal, based on the following established criteria \[[@CR11]\]: 0 (none), 1 (mild; staining around anus), 2 (moderate; staining around anus and top of hind legs) and 3 (severe; staining over legs and abdomen, often with continual oozing).

Histochemical, biochemical and morphometric assessment {#Sec6}
------------------------------------------------------

All experiments were performed in a blinded fashion. Blood and serum were sent to SA Pathology (Frome Road, Adelaide) for complete blood examination (CBE) and blood biochemistry tests (MBA-20). Formalin-fixed, paraffin-embedded jejunum and colon were cut into 4-μm sections and stained with haematoxylin and eosin for damage scoring, or alcian blue/periodic acid-Schiff mucin stain to assess changes in goblet cells \[[@CR12]\]. Immunohistochemistry to detect levels of caspase-3 (apoptosis marker) and ki67 (proliferation marker) \[[@CR13]\] was also performed on 4-μm formalin-fixed, paraffin-embedded sections. Microdissection to assess tissue morphometry (villous area and crypt depth) was performed as per established protocols \[[@CR11], [@CR14]\].

Tissue damage scoring {#Sec7}
---------------------

Histopathological changes in H&E-stained colon and jejunum were scored according to criteria described in Table [1](#Tab1){ref-type="table"}. Scores for each tissue section were tallied and represented as a percentage of the total score possible (20 for colon, 22 for jejunum).Table 1Tissue damage scoringJejunumColonCrypt ablation (CA)1 = markedly decreased length of crypts\
2 = complete ablation of crypts (ghost crypts)1 = markedly decreased length of crypts\
2 = complete ablation of crypts (ghost crypts)Flattening of colonic folds (FC)N/A1 = moderate flattening of folds and loss of surface area\
2 = marked flattening of folds (loss of more than half of normal folded area)Villous ablation/blunting (VA/B)1 = villi \< two thirds of normal length\
2 = villi \< one third of normal lengthNAVillous fusion (VF)1 = one or two fused villi throughout tissue\
2 = majority of villi fused throughout tissueN/AMucosal ulcerations (MU)1 = small superficial ulcerations\
2 = individual ulcerations (in total) involving approximately one third of intestinal circumference\
3 = large ulcerations involving more than half of the intestinal circumference1 = small superficial ulcerations\
2 = individual ulcerations (in total) involving approximately one third of intestinal circumference\
3 = large ulcerations involving more than half of the intestinal circumferenceInflammation (I) (increase in gut-associated lymphoid tissue, GALT)1 = widespread infiltrate of single WBCs\
2 = widespread infiltrate + patches of WBCs discrete from ulcerations1 = widespread infiltrate of single WBCs\
2 = widespread infiltrate + patches of WBCs discrete from ulcerationsApoptosis (A)1 = widespread distribution of single apoptotic cells in crypts\
2 = patches of crypt apoptosis in crypts1 = widespread distribution of single apoptotic cells in crypts\
2 = patches of crypt apoptosis in cryptsTissue disorganisation (TD)1 = disorientated crypts in some areas\
2 = disorientated crypts throughout tissue1 = disorientated crypts in some areas\
2 = disorientated crypts throughout tissueEpithelial cell sloughing (ECS)1 = discreet areas of lining epithelium sloughed into lumen\
2 = majority of lining epithelial layer gone1 = discreet areas of lining epithelium sloughed into lumen\
2 = majority of lining epithelial layer goneLymphatic congestion (LC)1 = Dilated lymph vessels or cystic collections of lymph\
2 = markedly dilated lymph vessels with large cystic collections of lymph1 = Dilated lymph vessels or cystic collections of lymph\
2 = markedly dilated lymph vessels with large cystic collections of lymphBlood vessel congestion (BVC)1 = few individual vessels full of RBCs in discreet areas\
2 = approximately half of blood vessels are full of RBCs throughout the entire tissue\
3 = majority of visible blood vessels completely full of RBCs, vessels appear distended1 = few individual vessels full of RBCs in discreet areas\
2 = approximately half of blood vessels are full of RBCs throughout the entire tissue\
3 = majority of visible blood vessels completely full of RBCs, vessels appear distended

Statistical analyses {#Sec8}
--------------------

*P* values in the text represent two-way ANOVA with Bonferroni post hoc testing, unless specified otherwise.

Results {#Sec9}
=======

Bodyweight {#Sec10}
----------

There was a clear separation in bodyweights 1 day post-irinotecan administration, whereby animals receiving irinotecan lost 5 % of bodyweight (approximately 10 g), regardless of experimental group, compared to untreated animals (Fig. [1a, b](#Fig1){ref-type="fig"}). On day 2, this separation reached significance (*P* \< 0.0001, Fig. [1a, b](#Fig1){ref-type="fig"}) and continued throughout the study. While irinotecan-treated animals gavaged with 500 mg/kg SBI lost less weight than other groups, this failed to reach significance (*P* = 0.10; Fig. [1a, b](#Fig1){ref-type="fig"}).Fig. 1**a** Bodyweight as percentage change from baseline. **b** Bodyweight in grams. *Graphs* represent data ± SEM. Data was analysed via two-way ANOVA, with the Bonferroni post hoc test

Clinical signs of stress and diarrhoea {#Sec11}
--------------------------------------

There were no clinical symptoms in the 4-day pre-treatment period, so data are presented from day 0 onwards. Peak symptom incidence and severity in treated controls were on day 3, with 82 % of animals experiencing symptoms, 16 % of these with severe symptoms (Fig. [2a](#Fig2){ref-type="fig"}). Administration of 250 mg/kg SBI reduced the overall incidence and severity of symptoms from days 1--5, with complete resolution of symptoms by day 5, 11 % less animals experiencing grade 3 symptoms overall and 28 % less experiencing grade 2 symptoms (Fig. [2b](#Fig2){ref-type="fig"}). Administration of 500 mg/kg SBI also reduced the overall incidence and severity of symptoms from days 1 to 6, with 11 % less animals experiencing grade 3 symptoms overall (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2Incidence of clinical signs of stress and diarrhoea. *Graphs* represent incidence of daily scores for each group, expressed as a percentage. Statistical significance for decreased grade 3 diarrhoea on day 3 in animals treated with 500 mg/kg SBI and irinotecan vs irinotecan controls (log rank *P* value = 0.0219, 31 vs 62 %) is marked with an *asterisk*

All rats receiving irinotecan developed diarrhoea, which peaked on days 3 and 4; administration of SBI reduced the overall incidence, severity and duration of irinotecan-induced diarrhoea (Fig. [2d--f](#Fig2){ref-type="fig"}). Incidence of grade 2 diarrhoea was reduced in animals gavaged with 250 mg/kg SBI (Fig. [2e](#Fig2){ref-type="fig"}) compared to treated controls (Fig. [2d](#Fig2){ref-type="fig"}) on day 0 (6 vs 9 %), day 2 (4 vs 29 %), day 3 (18 vs 19 %) and day 4 (27 vs 44 %), and incidence of grade 3 diarrhoea was reduced on day 3 (50 vs 62 %) and day 5 (14 vs 25 %). This reduction was even more pronounced in animals gavaged with 500 mg/kg SBI, with all diarrhoea symptoms resolving by day 5 (Fig. [2f](#Fig2){ref-type="fig"}), and a reduction in grade 2 diarrhoea compared to treated controls on day 0 (0 vs 9 %), day 2 (13 vs 29 %), day 4 (21 vs 44 %), and a reduction of grade 3 diarrhoea on day 2 (0 vs 17 %), a significant reduction on day 3 (log rank *P* value =0.0219, 31 vs 62 %), and reductions on day 4 (29 vs 31 %) and day 5 (0 vs 25 %).

Necropsy {#Sec12}
--------

Upon necropsy, animals treated with irinotecan (especially treated controls compared to SBI-gavaged animals) had an inflamed peritoneal cavity, particularly in the intestines and mesentery. SBI-administered animals also had less pronounced intestinal lymphatic nodules (Peyer's patches) than treated controls. While there were significant differences in organ weights at necropsy in all irinotecan-treated animals compared to untreated controls, post hoc analyses failed to identify specific differences associated with SBI administration.

CBE and MBA-20 {#Sec13}
--------------

There were no significant changes in all untreated, SBI-gavaged groups compared to untreated controls; these groups have therefore been omitted from graphs to enhance visual clarity. Administration of SBI had no influence on any MBA-20 parameters.

Six hours after irinotecan treatment, there was an increase in the white cell count (WCC) in irinotecan-treated groups (Fig. [3a](#Fig3){ref-type="fig"}) that was largely driven by an increase in neutrophil numbers (Fig. [3b](#Fig3){ref-type="fig"}) and was less pronounced in groups given SBI, although this failed to reach significance. On days 2 and 4 post-treatment, WCCs in irinotecan-treated groups were significantly decreased compared to untreated controls (*P* \< 0.0001), with SBI-gavaged groups showing a less pronounced, non-significant decrease at these time points (Fig. [3a](#Fig3){ref-type="fig"}). On day 6 post-treatment, however, WCCs in 250 mg/kg SBI-gavaged animals remained significantly lower than untreated and treated controls (*P* = 0.0141 and *P* = 0.0018, respectively, Holm-Sidak *t* test), suggesting that WCCs in this group had failed to reach normal levels by the end of the study. Animals administered 500 mg/kg SBI also had lower WCC than untreated controls at the end of the study; however, this failed to reach significance (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3Total white cell count (WCC) and neutrophil and lymphocyte levels as a percentage of the total WCC. *Graph* represents data ± SEM. Data was analysed via two-way ANOVA, with the Bonferroni post hoc analysis

At 6 h post-irinotecan treatment, there was a highly significant increase in neutrophils (as % of total WCC) in irinotecan groups (Fig. [3b](#Fig3){ref-type="fig"}; *P* \< 0.0001); however, this increase was less pronounced in groups administered SBI (non-significant; Fig. [3b](#Fig3){ref-type="fig"}). A similar pattern was observed 2 days post-irinotecan treatment. At 4 days post-treatment, all irinotecan-treated animals showed a significant neutropenia when compared to untreated controls (*P* \< 0.0001); however, post hoc analyses failed to identify differences between SBI-gavaged animals and treated controls. After 6 days, neutrophil levels in all irinotecan-treated groups had recovered almost to normal levels; however, animals administered 500 mg/kg SBI were significantly closer to normal levels (untreated controls) than treated controls (Fig. [3b](#Fig3){ref-type="fig"}; *P* = 0.04959, Holm Sidak *t* test).

Conversely, at 6 h and 2 days post-irinotecan treatment, lymphocyte levels (as % of total WCC) were significantly decreased in all irinotecan groups and significantly increased on day 4 compared to untreated controls (Fig. [3c](#Fig3){ref-type="fig"}; *P* \< 0.0001). These changes were less marked in SBI-gavaged groups (non-significant). This trend reached significance 6 days post-irinotecan treatment in both SBI groups versus treated controls (Fig. [3c](#Fig3){ref-type="fig"}; *P* = 0.0469, *P* = 0.0035, respectively, Holm Sidak *t* test), where percentage of lymphocytes approached normal levels (untreated controls). Similarly to neutrophil levels, recovery of lymphocytes to normal levels was more pronounced in animals administered SBI compared to treated controls.

Histology and tissue damage scoring {#Sec14}
-----------------------------------

There was a greater degree of irinotecan-induced damage in the colon than the jejunum (Fig. [4a, f](#Fig4){ref-type="fig"}), regardless of experimental group. In sections of jejunum from treated controls, villous atrophy, blunting and fusion was marked (Fig. [4b](#Fig4){ref-type="fig"}), and in colon and jejunum, cryptolysis was widespread, with severe attenuation of lining enterocytes, presence of apoptotic bodies in crypts, marked polymorphonuclear cell infiltrate within the lamina propria and accumulation of mucous and cellular debris within an enlarged lumen (Fig. [4b, d](#Fig4){ref-type="fig"}, g, i). Peyer's patches within the submucosa were often enlarged. Irinotecan-treated intestinal tissues also demonstrated an increased vascularity within the lamina propria (Fig. [4b](#Fig4){ref-type="fig"}) and dilated lacteals, which were often congested with lymphatic fluid. Pathological changes had for the most part resolved by day 6 post-treatment; however, in some tissues, villous fusion and blunting, lymphatic dilation and inflammation were still observed (Fig. [4d](#Fig4){ref-type="fig"}, i).Fig. 4H&E-stained 4-μm sections of jejunum and colon. *Bars* represent 100 μm; all sections, original magnification ×100. **a** Untreated colon. **b** Irinotecan-treated colon 6 h post-treatment. *Arrows* show apoptosis (*A*), mucus/epithelial cell sloughing (*M*/*ECS*), tissue disorganisation (*TD*) and crypt ablation (*CA*). **c** SBI-treated, irinotecan-treated colon, 6 h post-treatment. Note less TD, less CA, less A, than in **b. d** Irinotecan-treated colon 6 days post-treatment. *Arrows* show polymorphonuclear cells (PMNs) within the lamina propria. **e** SBI-treated, irinotecan-treated colon, 6 days post-treatment. Note less PMN infiltrate than in **d. f** Untreated jejunum. **g** Irinotecan-treated jejunum 6 h post-treatment. *Arrows* show villous ablation/blunting/fusion (*VA*/*B*/*F*), PMNs, A, CA, TD and blood vessel congestion (*BVC*). **h** SBI-treated, irinotecan-treated jejunum, 6 h post-treatment. Note less TD, less VA/B/F, less A, less BVC than in **g. i** Irinotecan-treated jejunum 6 days post-treatment. *Arrows* show PMN infiltrate, villous fusion (*VF*) and lymphatic congestion (*LC*). **j** SBI-treated, irinotecan-treated jejunum, 6 days post-treatment. Note higher degree of tissue organisation, no LC or VF, and slightly less PMN infiltrate in the lamina propria

Irinotecan-treated tissues from groups administered SBI at both 250 and 500 mg/kg displayed similar changes to those seen above; however, there was a visible decrease in crypt ablation (jejunum and colon; Fig. [4c, h](#Fig4){ref-type="fig"}) and villous ablation (jejunum, Fig. [4c, e](#Fig4){ref-type="fig"}) compared to treated controls (Fig. [4b, g](#Fig4){ref-type="fig"}). Overall, tissue architecture was preserved more noticeably in tissues derived from SBI-gavaged animals compared to treated controls (Fig. [4c, e, h, j](#Fig4){ref-type="fig"}). Presence of apoptotic cells within crypts at 6 h (Fig. [4c, h](#Fig4){ref-type="fig"}) and 2 days post-treatment was less prominent in jejunum and colon tissue derived from SBI-administered animals. Inflammatory cell infiltrate was also less pronounced.

Histopathological changes were then quantitated using the damage scoring system (Table [1](#Tab1){ref-type="table"}). Untreated, SBI-gavaged animals showed very low damage scores (0--1) similar to untreated controls and so have been omitted from graphs.

Administration of SBI resulted in significantly lower damage scores at all time points in jejunum and colon (Fig. [5](#Fig5){ref-type="fig"}; *P* \< 0.0001). This reduction in irinotecan-induced damage reached significance in 250 mg/kg SBI-gavaged animals compared to treated controls, at 6 h post-treatment in jejunum (Fig. [5a](#Fig5){ref-type="fig"}; 35.8 ± 1.81 vs 44.0 ± 2.54) and colon (Fig. [5b](#Fig5){ref-type="fig"}; 30.7 ± 2.97 vs 43.6 ± 2.83), 2 days post-treatment in jejunum (Fig. [5a](#Fig5){ref-type="fig"}; 42.6 ± 4.62 vs 57.6 ± 3.83) and colon (Fig. [5b](#Fig5){ref-type="fig"}; 25.6 ± 1.75 vs 36.3 ± 2.80) and at 6 days post-treatment in jejunum (Fig. [5a](#Fig5){ref-type="fig"}; 9.99 ± 3.64 vs 21.6 ± 2.06) and colon (Fig. [5b](#Fig5){ref-type="fig"}; 13.6 ± 2.61 vs 26.4 ± 2.37). Administration of 500 mg/kg SBI also significantly reduced irinotecan-induced damage in the colon at 6 h post-treatment (Fig. [5b](#Fig5){ref-type="fig"}; 33.1 ± 3.77 vs 43.6 ± 2.83; *P* \< 0.0001), 2 days post-treatment (Fig. [5b](#Fig5){ref-type="fig"}; 22.9 ± 3.06 vs 36.3 ± 2.80), and 4 days post-treatment (Fig. [5b](#Fig5){ref-type="fig"}; 29.2 ± 2.39 vs 37.1 ± 2.41) and 6 days post-treatment in the jejunum (Fig. [5a](#Fig5){ref-type="fig"}; 13.6 ± 2.83 vs 21.6 ± 2.06) and colon (Fig. [5b](#Fig5){ref-type="fig"}; 18.1 ± 3.13 vs 26.4 ± 2.37).Fig. 5Tissue damage scores. *Graph* represents data ± SEM. Data was analysed via two-way ANOVA, with the Bonferroni post hoc analysis. *Asterisks* represent significance when compared to treated controls (*P* \< 0.0001)

Alcian blue, periodic acid/Schiff staining of goblet cells {#Sec15}
----------------------------------------------------------

Increased numbers of cavitated goblet cells have been associated with chemotherapy-induced gut injury \[[@CR15]\]; in this study, however, there were no significant differences attributable to SBI treatment.

Morphometry {#Sec16}
-----------

In the jejunum, villous area of all irinotecan-treated animals was significantly increased on day 6 post-treatment compared to untreated controls (*P* \< 0.0001; due to rebound hyperplasia); however, SBI administration was not associated with any significant differences between groups.

Immunohistochemistry to assess proliferation and apoptosis {#Sec17}
----------------------------------------------------------

Levels of proliferating and apoptotic cells were consistent with irinotecan treatment; however, analysis failed to highlight differences between SBI-gavaged and saline-treated animals in either the jejunum or colon.

Discussion {#Sec18}
==========

In the current study, twice daily administration of SBI was well-tolerated and resulted in reduction in the incidence, severity and duration of irinotecan-induced clinical signs of stress and diarrhoea, as well as a significant reduction in histopathological damage in the intestines. There is evidence that the basis for these observations is modulation of the inflammatory response associated with irinotecan-induced mucositis. The results herein are consistent with results observed in similar animal intestinal studies, where SBI was utilized, and also show similar symptom reduction as seen in patient studies of enteropathies managed with SBI.

Since chemotherapy-induced GI mucositis (CIGM) has a similar etiology and symptom profile to intestinal disorders such as IBS-D and HIV-associated enteropathy, it is reasonable to suggest that patients suffering from CIGM would show similarly improved symptoms with SBI. The animal model used in this study has been well established and has many similarities to the patient setting; thus, we postulated that administration of SBI would manage CIGM.

In a pilot study of 66 patients by Wilson et al. \[[@CR8]\], daily administration of 10 g of SBI over a period of 6 weeks significantly reduced the severity and frequency of symptoms of IBS-D, such as abdominal pain, stool frequency, loose stools, bloating, flatulence and urgency, compared to placebo (soy protein isolate). Similarly, in a study of eight patients with HIV-associated enteropathy by Asmuth \[[@CR10]\], twice daily administration of 2.5 g SBI for 8 weeks resulted in reduced bowel movements and improved stool consistency in all patients. In the current study, irinotecan-treated rats gavaged with human equivalent doses of SBI also showed a significant reduction in the incidence, severity and duration of mucositis-associated symptoms, such as diarrhoea.

Since the animals in this model were administered SBI 4 days prior to irinotecan treatment, it would be interesting to see whether a longer period of pre-treatment SBI administration would further improve diarrhoea and clinical symptoms of stress. Such preparatory dosing would also be possible in patients with CIGM (if SBI was given before irinotecan administration); however, since patients with other enteropathies present with these conditions before SBI administration would be possible, benefits of preparatory dosing in these conditions will remain unknown. A future animal study to determine whether dosing with SBI at the onset of mucositis symptoms (without preparatory dosing) is able to achieve the same results as the current study would provide useful information on the value of pre-treatment and determine whether protective effects of SBI are transient or cumulative.

The lack of changes in bodyweights, organ weights, intestinal goblet cells, morphometry, apoptosis and proliferation suggest that SBI-associated attenuation of the clinical symptoms of mucositis is not dependent upon increased cell proliferation and tissue growth as is observed after treatment with growth factors designed to alleviate mucositis \[[@CR16], [@CR17]\]. Similar findings were made in rotavirus-infected pigs \[[@CR18]\], where SBI administration did not significantly increase weight gain or alter tissue morphometry, and in weaning piglets, where SBI administration showed few changes to intestinal morphometry, and in fact resulted in lower small intestinal weight over the treatment period \[[@CR19]\].

SBI is high in glutamic acid, which is converted to glutamine. Studies have shown that free glutamine is an essential amino acid required during times of catabolic stress, such as injury or disease, and is a preferential energy source not only for enterocytes but also for rapidly proliferating immune cells \[[@CR20], [@CR21]\]. It is thus linked to the maintenance of intestinal barrier function and cell differentiation and may contribute to the positive effects of SBI as observed in this study, where histopathological analyses showed that tissues from animals administered SBI were more likely to retain proper architecture and an intact epithelial layer.

One hypothesis for the positive effects of SBI in enteropathic conditions is the modulation of intestinal immune function in gut-associated lymphoid tissue (GALT) and reduced levels of pro-inflammatory cytokines \[[@CR7], [@CR22], [@CR23]\]. Oral administration of spray-dried plasma proteins was associated with a decreased level of inflammatory cytokines in organised (Peyer's patches) and diffuse (lymphocytes in lamina propria) GALT of the ileum and colon in weaning piglets, which show similar symptoms to patients suffering from GI mucositis, including malabsorption, diarrhoea and weight loss associated with increased gut permeability \[[@CR7]\]. Results obtained in the current study reflect these findings, as levels of circulating and mucosal neutrophils and lymphocytes (diffuse GALT) in irinotecan-treated animals receiving SBI were lower than those in treated controls. Anecdotal evidence of less pronounced intestinal lymphatic nodules (organised GALT) and less inflamed peritoneal cavities during necropsy also supports this. Further studies to assess tissue levels of pro-inflammatory cytokines are currently underway.

Analysis of histopathological damage showed significantly lower damage scores in both colon and jejunum of irinotecan-treated animals that had received both 250 and 500 mg/kg SBI, compared to those that had not. The density of lymphoid cells present in the lamina propria was decreased in gut tissues from animals gavaged with SBI, which was reflected in comparatively lower total white cell counts and percentages of neutrophils and lymphocytes in circulating blood. Reduced damage scores were most pronounced 2 and 4 days post-treatment in tissues from animals receiving SBI compared to treated controls. This also supports the potential anti-inflammatory role of SBI, suggesting that preparatory dosing prior to irinotecan treatment is not enough to stop the initial damage but helps to attenuate the induced inflammatory state which further drives the damage.

Low-grade inflammation, either idiopathic or injury-induced, is associated with increased epithelial permeability in the gut due to degradation of occludin within tight junctions \[[@CR24]\]. Transepithelial bacterial translocation is then more likely to occur, thus increasing lipopolysaccharide exposure to the GALT, which then further drives the process through the release of pro-inflammatory cytokines, giving rise to clinical symptoms such as diarrhoea, malabsorption and subsequent weight loss. The process is thought to underpin chronic diseases such as IBS-D \[[@CR8]\] and HIV-associated enteropathy \[[@CR10]\], and physiologically stressful conditions such as malnutrition \[[@CR6]\] and weaning \[[@CR25]\], and is often accompanied by changes to the microbiota, which may further compound the inflammatory process. Gastrointestinal mucositis initiated by cancer therapy (chemotherapy, radiotherapy and targeted therapy) occurs through direct damage to gut epithelium and creation of reactive oxygen species; however, the subsequent mechanisms of inflammation, increased gut permeability and clinical symptoms are similar to the abovementioned conditions. It has been shown that IgG in SBI binds lipopolysaccharide from bacterial cell walls, thus protecting mucosal surfaces from bacterial antigenic exposure \[[@CR26], [@CR27]\]. Similar binding effects have also been demonstrated for endotoxins \[[@CR22], [@CR28], [@CR23]\] and rotavirus \[[@CR18]\], further underpinning the importance of SBI in management of enteropathies \[[@CR29], [@CR30]\]. Additional studies to explore the role of SBI in attenuating the intestinal inflammatory response and possible maintenance of the healthy microbiota in this animal model are currently underway.

The results from this study demonstrate that SBI shows significant promise in the management of chemotherapy-induced GI mucositis in an animal model. Positive effects of SBI in the management other enteropathies with similar symptom profiles in patients have also been demonstrated, perhaps paving the way for similar use of SBI in the supportive care of treatment-induced mucositis. Further studies to underpin exact mechanisms of action and effects on solid tumours are required, however, as well as comprehensive analyses of pro-inflammatory cytokines within gut tissue and microbiome alterations.
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